THE-BRIJ
19.12.2022 12:53:36 CET | Business Wire | Press release
Serendipity Arts today announced its vision to bring the arts to life through a cutting-edge arts and culture centre, that will be a bridge that connects the world to the arts, and its transformational power. THE BRIJ will dedicate space, time, and resources to create ground-breaking art that is transformational and meaningful. Through this centre, Serendipity Arts also hopes to spark conversations around the arts across the South Asian region worldwide, assimilating regional flavours, traditions, and cultures, while also building a sustainable artistic ecosystem. The upcoming institution is named after and pays homage to late Mr. Brijmohan Lall Munjal, Indian industrialist and visionary, Mr. Sunil Kant Munjal’s father.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221218005083/en/
Outlining the idea behind THE BRIJ, Mr. Sunil Kant Munjal, Founder & Patron of Serendipity Arts and Founder of THE BRIJ, said, “Our privileges always come with responsibility; this initiative is a responsibility and a passion project for us. THE BRIJ stems from a responsibility we feel towards the arts; the way art is seen today, compared to how it was perceived in the region, prior to colonization. In terms of its programming, THE BRIJ will retain the aura of the flagship festival while adding multiple layers of practice, learning and experimentation to its programs, around the year. Planned around diverse creative practices, the facility will have higher arts education, incubation labs, centres of cultural innovation, performance spaces, and museums at a never-before-seen scale, in an interdisciplinary manner. In effect it will be the complete ecosystem for Arts & Culture at one place.”
The three essential elements of the Centre will be Education & Research, Multidisciplinary Experiences and Innovation & Incubation with training, workshops, and residencies. The one-of-its-kind centre is currently under construction and will have a Museum, an Academy & Workshop, a Gallery, Library, a Stepwell Gallery, an Arena, Theatre and Black Box, and much more. The facility will also house a crafts centre and an artisanal village, where dying and fringe art & craft forms will be brought back to life, through research, practice, and incubation. The entire campus has been designed in a way that it is 100 percent accessible to the differently abled.
With interdisciplinarity, education, and intergenerational exchange as its key purposes, THE BRIJ will emphasise excellence, change, innovation, equality, integrity, and responsibility. The aim is to gift the city of Delhi and the nation a cultural centre, enabling visitors with a shared passion and curiosity for the arts to cherish and immerse in it, inclusively. The centre hopes to create a space that attracts academics, intellectuals, students, art lovers, critics, artists, and members of the public, who can come together to create a bustling creative community.
With cutting-edge technologies that promise to bring forth unique and engaging experiences for visitors, THE BRIJ will be truly global in form and spirit. It will have all the ingredients for an inclusive and immersive experience with assisted navigation and omnichannel availability, while also driving the imperatives of sustainability through a reduced carbon footprint. At the same time, an efficient operational backend, a robust infrastructure for security and connectivity, and futuristic technologies will support the museum and the dream.
Speaking about THE BRIJ, Ms Smriti Rajgarhia, Director, Serendipity Arts Foundation and Festival, said, “THE BRIJ is our endeavour to strengthen India’s place in the global cultural dialogue and make international art accessible to the discerning and the common enthusiast. We aim to contribute to the cultural quotient of the region, through restored artworks and revival of lost or at-risk art forms, while also seeking to redefine the future of arts through interdisciplinary collaboration and innovation.”
Among the many features that make this cultural centre unique are the twin driving forces of economy and sustainability, both of which find expression through this building. THE BRIJ will also aim to meet the Foundation’s aspiration to emerge as a catalyst for change, by creating employment opportunities, contributing to India’s and New Delhi’s cultural economy and attracting both Indian and international tourists. Courtesy of Serendipity Arts, THE BRIJ already has and will further enhance its partnerships and exchanges with global institution and creative organizations, to build a facility with state-of-the-art infrastructure, that is organic and future facing.
The entire campus of THE BRIJ would have a platinum rating for green buildings and will generate more than 5200 direct and indirect employment. Besides, more than 120,000 people are expected to benefit from the education and skilling programmes that will be made available. About 90,000 young learners will have free access to the museum, with over 200 art start-ups and projects supported through the incubation centre. Through its multilateral and multicultural platform, the one-of-its-kind Museum hopes to significantly contribute to India’s GDP.
Speaking on the initiative, key member of our expert panel of architects, Mr. Dikshu Kukreja, Managing Principal, CP Kukreja Architects (CPKA), New Delhi, said, “The design philosophy for THE BRIJ is to create a co-existential architecture where the building and landscape dissolve into one. The architecture amplifies its context with buildings envisioned as magnified rock outcrops just like the quartzite rock formations found on the site. The design allows the adjoining forest to permeate into the site. All this as the vibrant and varied programmatic elements form a musical ensemble experiencing hitherto unexplored and futuristic sustainable design strategies.”
In addition to Mr Sunil Kant Munjal, THE BRIJ is also the dream of patron and social entrepreneur Shefali Munjal, Founder-Patron of THE BRIJ. The Board of Advisors include media personality and the current Chair of the Royal College of Arts, UK, Sir Peter Bazelgette; Harsh Goenka, Chairman of the RPG Group, an ardent collector of art and a strong advocate for fostering innovation; and Deepak Iyer, who heads the Accenture Microsoft Business group for Southeast Asia.
Advisors for THE BRIJ include poet, cultural theorist, and curator Ranjit Hoskote; Manu Chandra, Chef Partner for THE BRIJ and one of the pioneers of the gastropub scene in India; Shubha Mudgal, Padma Shri recipient and winner of the Gold Plaque Award for Special Achievement in Music at the Chicago International Film Festival; Aneesh Pradhan, noted table player; and Anuradha Kapur, recipient of the Sangeet Natak Award for Direction in Theatre and the instrumental figure at the National School of Drama, Delhi and Bangalore.
For more details, visit www.thebrij.world
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221218005083/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
